Published in J Nucleic Acids on September 17, 2012
Recent advances in chemical modification of Peptide nucleic acids. J Nucleic Acids (2012) 0.82
Putting an 'End' to HIV mRNAs: capping and polyadenylation as potential therapeutic targets. AIDS Res Ther (2013) 0.76
Single-molecule FRET studies of HIV TAR-DNA hairpin unfolding dynamics. J Phys Chem B (2014) 0.75
Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages. EMBO J (1998) 2.45
Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J Virol (1995) 1.69
Cell-penetrating-peptide-based delivery of oligonucleotides: an overview. Biochem Soc Trans (2007) 1.49
TAR RNA loop: a scaffold for the assembly of a regulatory switch in HIV replication. Proc Natl Acad Sci U S A (2002) 1.44
Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. Mol Pharmacol (1974) 1.37
In vitro selection identifies key determinants for loop-loop interactions: RNA aptamers selective for the TAR RNA element of HIV-1. RNA (1999) 1.24
Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: implications for mitochondrial DNA replication, expression and disease. Nucleic Acids Res (2001) 1.23
Specific HIV-1 TAR RNA loop sequence and functional groups are required for human cyclin T1-Tat-TAR ternary complex formation. Biochemistry (2002) 1.21
Is a closing "GA pair" a rule for stable loop-loop RNA complexes? J Biol Chem (2000) 1.16
Aptamers targeted to an RNA hairpin show improved specificity compared to that of complementary oligonucleotides. Biochemistry (2006) 1.02
Liquid-crystal NMR structure of HIV TAR RNA bound to its SELEX RNA aptamer reveals the origins of the high stability of the complex. Proc Natl Acad Sci U S A (2008) 0.99
LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA element of HIV-1. Nucleic Acids Res (2004) 0.97
Molecular dynamics reveals the stabilizing role of loop closing residues in kissing interactions: comparison between TAR-TAR* and TAR-aptamer. Nucleic Acids Res (2003) 0.97
Gene targeting and expression modulation by peptide nucleic acids (PNA). Curr Pharm Des (2010) 0.94
Discoveries of Tat-TAR interaction inhibitors for HIV-1. Curr Drug Targets Infect Disord (2005) 0.93
Modulation of RNA function by oligonucleotides recognizing RNA structure. Prog Nucleic Acid Res Mol Biol (2001) 0.92
Loop-loop interaction of HIV-1 TAR RNA with N3'-->P5' deoxyphosphoramidate aptamers inhibits in vitro Tat-mediated transcription. Proc Natl Acad Sci U S A (2002) 0.91
2'-O-methyl-RNA hairpins generate loop-loop complexes and selectively inhibit HIV-1 Tat-mediated transcription. Biochemistry (2002) 0.90
Peptide nucleic acid conjugates: synthesis, properties and applications. Curr Top Med Chem (2005) 0.90
A peptide nucleic acid-neamine conjugate that targets and cleaves HIV-1 TAR RNA inhibits viral replication. J Med Chem (2004) 0.89
Delivery of antisense peptide nucleic acids (PNAs) to the cytosol by disulphide conjugation to a lipophilic cation. FEBS Lett (2004) 0.89
Endogenous expression of an anti-TAR aptamer reduces HIV-1 replication. RNA Biol (2006) 0.87
Modulating viral gene expression by aptamers to RNA structures. Biol Cell (2003) 0.87
Inhibitors of HIV-1 Tat-mediated transactivation. Curr Med Chem (2006) 0.87
On the determination of availability of ligand binding sites in steady-state systems. J Theor Biol (1977) 0.86
NMR structure of a kissing complex formed between the TAR RNA element of HIV-1 and a LNA-modified aptamer. Nucleic Acids Res (2007) 0.86
Hairpin-forming peptide nucleic acid oligomers. Biochemistry (1998) 0.85
Hexitol nucleic acid-containing aptamers are efficient ligands of HIV-1 TAR RNA. Biochemistry (2005) 0.83
LNA derivatives of a kissing aptamer targeted to the trans-activating responsive RNA element of HIV-1. Blood Cells Mol Dis (2007) 0.83
An efficient biodelivery system for antisense polyamide nucleic acid (PNA). Oligonucleotides (2008) 0.82
Systematic screening of LNA/2'-O-methyl chimeric derivatives of a TAR RNA aptamer. FEBS Lett (2007) 0.82
RNA and N3'-->P5' kissing aptamers targeted to the trans-activation responsive (TAR) RNA of the human immunodeficiency virus-1. Nucleosides Nucleotides Nucleic Acids (2001) 0.79
Prospects for antisense peptide nucleic acid (PNA) therapies for HIV. Expert Opin Biol Ther (2009) 0.79
Solid-phase synthesis and thermal denaturation study of cyclic PNAs targeting the HIV-1 TAR RNA loop. Bioorg Med Chem Lett (2007) 0.77
Identification of cellular factors associated with the 3'-nontranslated region of the hepatitis C virus genome. Mol Cell Proteomics (2006) 1.21
Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production. J Virol (2002) 1.03
The FUSE binding protein is a cellular factor required for efficient replication of hepatitis C virus. J Virol (2008) 0.98
Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides. Nucleic Acids Res (2005) 0.98
Identification and evaluation of anti hepatitis C virus phytochemicals from Eclipta alba. J Ethnopharmacol (2012) 0.97
A PNA-transportan conjugate targeted to the TAR region of the HIV-1 genome exhibits both antiviral and virucidal properties. Virology (2005) 0.90
A peptide nucleic acid-neamine conjugate that targets and cleaves HIV-1 TAR RNA inhibits viral replication. J Med Chem (2004) 0.89
Anti HIV-1 virucidal activity of polyamide nucleic acid-membrane transducing peptide conjugates targeted to primer binding site of HIV-1 genome. Virology (2007) 0.89
Affinity capture and identification of host cell factors associated with hepatitis C virus (+) strand subgenomic RNA. Mol Cell Proteomics (2013) 0.88
Single acute-dose and repeat-doses toxicity of anti-HIV-1 PNA TAR-penetratin conjugate after intraperitoneal administration to mice. Oligonucleotides (2008) 0.88
Insertion of a small peptide of six amino acids into the beta7-beta8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities. BMC Biochem (2002) 0.87
STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 5' and 3' ends. Mol Cancer Ther (2008) 0.86
Inhibition of HIV-1 replication by anti-trans-activation responsive polyamide nucleotide analog. Antiviral Res (2002) 0.86
Mechanism of RNA cleavage catalyzed by sequence specific polyamide nucleic acid-neamine conjugate. Oligonucleotides (2007) 0.86
Pharmacokinetic analysis of polyamide nucleic-acid-cell penetrating peptide conjugates targeted against HIV-1 transactivation response element. Oligonucleotides (2008) 0.86
Synthesis, screening for antitubercular activity and 3D-QSAR studies of substituted N-phenyl-6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydro-pyrimidine-5-carboxamides. Eur J Med Chem (2007) 0.86
PNA targeting the PBS and A-loop sequences of HIV-1 genome destabilizes packaged tRNA3(Lys) in the virions and inhibits HIV-1 replication. Virology (2002) 0.83
Substitution of conserved hydrophobic residues in motifs B and C of HIV-1 RT alters the geometry of its catalytic pocket. Biochemistry (2002) 0.83
An efficient biodelivery system for antisense polyamide nucleic acid (PNA). Oligonucleotides (2008) 0.82
Immunological response to peptide nucleic acid and its peptide conjugate targeted to transactivation response (TAR) region of HIV-1 RNA genome. Oligonucleotides (2008) 0.81
A single deletion at position 134, 135, or 136 in the beta 7-beta 8 loop of the p51 subunit of HIV-1 RT disrupts the formation of heterodimeric enzyme. J Cell Biochem (2010) 0.81
Fluorescent labeling of human mesenchymal stem cells by thiophene fluorophores conjugated to a lipophilic carrier. Chem Commun (Camb) (2010) 0.81
Short peptide nucleic acids (PNA) inhibit hepatitis C virus internal ribosome entry site (IRES) dependent translation in vitro. Antiviral Res (2008) 0.80
A positively charged side chain at position 154 on the beta8-alphaE loop of HIV-1 RT is required for stable ternary complex formation. Nucleic Acids Res (2003) 0.79
Prospects for antisense peptide nucleic acid (PNA) therapies for HIV. Expert Opin Biol Ther (2009) 0.79
Polyamide amino acids trimers as TAR RNA ligands and anti-HIV agents. Bioorg Med Chem (2010) 0.79
Tumour-specific cytotoxicity and MDR-reversal activity of dihydropyridines. In Vivo (2006) 0.78
Design of novel rho kinase inhibitors using energy based pharmacophore modeling, shape-based screening, in silico virtual screening, and biological evaluation. J Chem Inf Model (2014) 0.78
A "ready-to-use" fluorescent-labelled-cysteine-TBTP (4-thiobutyltriphenylphosphonium) synthon to investigate the delivery of non-permeable PNA (peptide nucleic acids)-based compounds to cells. Bioorg Chem (2007) 0.78
Thermodynamic studies of a series of homologous HIV-1 TAR RNA ligands reveal that loose binders are stronger Tat competitors than tight ones. Nucleic Acids Res (2013) 0.78
Cyclic PNA-based compound directed against HIV-1 TAR RNA: modelling, liquid-phase synthesis and TAR binding. Org Biomol Chem (2003) 0.78
Impact of template overhang-binding region of HIV-1 RT on the binding and orientation of the duplex region of the template-primer. Mol Cell Biochem (2009) 0.78
Solid-phase synthesis and thermal denaturation study of cyclic PNAs targeting the HIV-1 TAR RNA loop. Bioorg Med Chem Lett (2007) 0.77
Affinity labeling of hepatitis C virus replicase with a nucleotide analogue: identification of binding site. Biochemistry (2013) 0.77
A cyclic PNA-based compound targeting domain IV of HCV IRES RNA inhibits in vitro IRES-dependent translation. Bioorg Med Chem (2005) 0.77
The glutamine side chain at position 91 on the β5a-β5b loop of human immunodeficiency virus type 1 reverse transcriptase is required for stabilizing the dNTP binding pocket. Biochemistry (2011) 0.77
Non-canonical effects of anthrax toxins on haematopoiesis: implications for vaccine development. J Cell Mol Med (2008) 0.76
The versatile nature of the 6-aminoquinolone scaffold: identification of submicromolar hepatitis C virus NS5B inhibitors. J Med Chem (2013) 0.76
Influence of the RNase H domain of retroviral reverse transcriptases on the metal specificity and substrate selection of their polymerase domains. Virol J (2009) 0.76
Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors. J Chem Inf Model (2014) 0.76
Polyamide amino acids: a new class of RNA ligands. Chem Commun (Camb) (2009) 0.76
New pyrazolobenzothiazine derivatives as hepatitis C virus NS5B polymerase palm site I inhibitors. J Med Chem (2014) 0.75
Novel 4-thiazolidinones as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase. Arch Pharm (Weinheim) (2014) 0.75
Exploring the impact of the side-chain length on peptide/RNA binding events. Phys Chem Chem Phys (2017) 0.75
AZT and AZT-monophosphate prodrugs incorporating HIV-protease substrate fragment: synthesis and evaluation as specific drug delivery systems. Antivir Chem Chemother (2006) 0.75
Synthesis and cellular uptake of a fluorescently labeled cyclic PNA-based compound. Bioorg Med Chem Lett (2004) 0.75